Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject in its Phase III clinical trial for BL-B01D1/iza-bren as a treatment for extensive-stage small cell lung cancer, according to a Shanghai bourse filing on Friday.
The drug is being tested in combination with a PD-1 monoclonal antibody versus platinum-based chemotherapy in combination with a PD-1 monoclonal antibody.
The pharmaceutical company's shares dropped 5% during the morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.